Blog

Peptides are the most-searched new clinic category of 2026 and the most misunderstood. FDA moved twelve peptides off its Category 2 list in April, an advisory committee reviewed seven of them in July, Hims says it has six ready to launch, and none of that has made BPC-157 legal to prescribe yet. Here is the legal map as of September 2026, the peptides a clinic can actually offer today, the launch stack, what it costs to do it yourself versus on a platform, and the day-one plan for when the FDA list finally moves.

In 2026 the white-label telehealth category split into a flat-fee lane: Remedora at $200 a month, Karpa from $297, Cuvo at $997 or $2,000 plus $25 a consult, and a handful of others with numbers on their pricing pages. We are the fourth name in this comparison and we do not publish a price yet, so we wrote it with the rules from our other comparisons: only public numbers, plain statements about who each platform is for, and the questions to ask each of us before signing.

Yes, a nurse practitioner can start a telehealth weight loss practice, and in the roughly 28 states with full practice authority the NP can own it outright. The work is in the details that Reddit threads argue about at two in the morning: the collaborating physician who costs 'the most painful $700 a month', the state-by-state licensing, malpractice at $2,400 a year, and the choice between insurance that pays thirty cents on the dollar and cash pay that does not. Here is the whole path, with prices.

Is it too late to start a GLP-1 telehealth business? Too late for the 2024 version, where a $99 compounded vial and a Facebook ad account made a company. Not too late for the version that is actually working in the third quarter of 2026: a niche, a retention system, branded drugs the manufacturer ships, and fixed costs low enough that 500 patients is a business. Here is what died, what the numbers say still works, and the three things that now count as a moat.

The fourth quarter of 2026 has more dated decisions stacked into it than any quarter since the shortage ended: a 503B final order that can land any week, a DEA rule sitting at the White House since August 25, a CagriSema decision, a $199 manufacturer promo that expires December 31, and an open-enrollment season in which employers are quietly dropping GLP-1 coverage. Here is every date we know, what is still undated, and the build item that belongs in front of each one.

If you are shopping for an OpenLoop alternative in September 2026, the honest shortlist has nine names across three lanes, and the differences that matter are not features. They are who publishes a price, who holds the merchant account and the patient relationship, and how many weeks pass before your first patient. Here is the table, the questions the January breach added to every vendor call, and where we fit.

LegitScript certification costs $975 to apply and $2,150 a year per website, takes anywhere from two business days on the expedited path to eleven weeks doing it yourself, and gates Meta, Google, Microsoft and TikTok ads for any telehealth brand. Founders on Reddit call the process 'confusing af', and the confusion is mostly about who does the work. Here are the nine standards, the documents, the realistic timelines, the compounded-GLP-1 problem, and what a platform can and cannot do about any of it.

A cash-pay telehealth brand in late 2026 keeps somewhere between $60 and $115 of every $149 membership after clinical, platform, processing and support costs, before marketing. At 100 patients that is a side business, at 500 it is a real company, and at 2,000 it is a company with a support team and a tax problem. Here is the model with every assumption exposed, the public-company numbers it is checked against, and the one cost decision that moves the answer more than price does.

A fitness YouTuber announced his own hormone and peptide clinic in September ('I personally selected the practitioners'), Karpa Health lists creators as a customer segment on its pricing page, and the founder who built Medvi did it, in the words of one investigation, with 800 fake Facebook accounts posing as doctors. Creator-launched health brands are the fastest-growing kind of DTC telehealth company and the easiest to get sued for. Here are the two models, the launch stack, the economics of an audience that costs nothing to acquire, and the rules that decide whether the creator is a founder or an exhibit.

Founders on Reddit have stopped asking which platform has the best features and started asking who owns the patient, the records, the card tokens, the pharmacy contract, and the domain when the relationship ends. Those are the right questions, and most sales pages do not answer them. Here are the five ownership dimensions, what each model gives you, the contract language to demand, and where Turbopills stands.

The telehealth platforms are now pitching pharmacies directly ('add virtual care programs to your pharmacy, no extra staff'), and a compounding pharmacy's own trade press warns that clinics without exclusive pharmacy partnerships 'face attrition to CVS, Amazon Pharmacy, and telehealth platforms.' A pharmacy that has watched a third of its GLP-1 volume disappear with the shortage has a choice: rent patients from a platform, sign exclusivity with clinics, or put its own brand on a front end and keep the patient. Here is what the third option requires, from the clinical entity to the storefront, and where the lines are.

CVS sells a $29 online weight-loss visit with no membership, Walgreens charges $49, Amazon One Medical charges $39 for a message and $59 for video, and by early Q4 the CVS app will show Lilly's cash prices with same-day pickup at 9,000 stores. Retail has priced the visit as a loss leader for the pharmacy. An independent brand that tries to match it is competing with a pharmacy's margin using a clinic's costs. Here is what retail does not do, the three positions that still win, and the pricing design patients told us they want.

Since April 1, 2026, a merchant whose fraud reports plus disputes exceed 1.5% of settled card-not-present transactions is 'excessive' under Visa's Acquirer Monitoring Program, pays $8 per disputed or fraudulent transaction, and becomes a problem for an acquirer that already treats telehealth as a restricted category. For a 500-patient subscription program that is seven bad transactions in a month. Here is how the ratio is counted, where telehealth disputes actually come from, and the billing settings that keep a program under the line.

The pages that rank for 'telehealth CRM' were written in 2022 and 2023 and recommend Salesforce, Zoho and Zendesk to everyone. A DTC telehealth brand has a narrower problem: it needs a system that knows a patient's clinical state, holds protected health information legally, and runs the five workflows that decide conversion and retention, without turning the marketing tool into a medical record. Here are the five realistic options, what each costs in 2026, the test that generic CRMs fail, and what to use at each stage.

On July 29, 2026 the FTC, Utah and Los Angeles County sued Hims & Hers over three things every DTC telehealth brand does or has been tempted to do: charging at intake before a provider has looked at the case, hiding the cancel button, and sending patient events to Meta and Snap. Hims says the claims are baseless and will fight them. Whatever the court decides, the complaint is the clearest checkout specification the category has ever been handed. Here is the spec.

Every platform demo is a performance, and the performance always goes well. This scorecard is how you take control of it: 40 questions across eight areas, each paired with the answer that should worry you, scored live on a 0-1-2 scale. Copy it, send it ahead, and let the reactions do the diligence.

January is the biggest demand month in DTC telehealth, and the programs that win it are built in September, not December. Provider capacity, support staffing, pharmacy commitments, ad staging, and load tests all have lead times measured in months. This is the build list, laid out on a September-to-December timeline, with the two failure points that break first: intake review queues and lead response time.

Prescription skincare is the most natural telehealth vertical for a wellness brand that already has an audience: visual results, cash-pay pricing, creator-native acquisition, and a 90-day refill rhythm that compounds. The clinical spine is photo-based async review, which means the whole program rides on the quality of the pictures your intake collects. Here is the launch playbook: the photo spec, the entry SKUs, the pharmacy decision, and the expansion path.

Novo filed CagriSema on December 18, 2025 and says a US decision is expected in Q4 2026, with no public PDUFA date. Retatrutide has drifted to an early-2027 filing, which makes CagriSema the next-molecule drill your program actually has to run. Readiness is not predicting the outcome: it is education pages on an update rhythm, formulary logic that adds a molecule as configuration, pricing scenarios drafted in advance, and a day-one kit ready to ship within hours.

Every October, plan documents land and a wave of patients discovers their GLP-1 coverage changes January 1. They are not new leads: they are experienced patients, mid-treatment, angry at a decision someone else made about their care. The funnel that receives them well, dedicated landing page, coverage-aware intake, honest bridge pricing, gets designed in September. Here is the blueprint, including the copy that works and the copy that repels.